Zusammenfassung
Eine Erkrankung der Makula ist in den Industrienationen der häufigste Grund für eine Erblindung. Nach WHO-Daten von 2002 sind die Ursachen hierfür in den Industrienationen zu 50% auf die altersabhängige Makuladegeneration (AMD) und zu ca. 18% auf die diabetische Retinopathie zurückzuführen (Resnikoff et al. 2004). Große Hoffnung für die Behandlung der exsudativen Form der AMD brachte die Einführung einer lokalen Therapie am Auge, die den »vascular endothelial growth factor« (VEGF) hemmt. Der Wachstumsfaktor VEGF spielt sowohl bei der AMD als auch bei der diabetischen Retinopathie eine entscheidende Rolle bei der Entstehung und Progression. Inhibitoren von VEGF sind zugelassene Medikamente für die Behandlung der altersabhängigen Makuladegeneration seit 2004. Die erste Zulassung erhielt Pegaptanib (Macugen®, Fa. Pfizer) und kurz darauf Ranibizumab (Lucentis®, Fa. Novartis). Zusätzlich zu den zugelassenen Präparaten findet sich eine breite Anwendung von Bevacizumab (Avastin®, Fa. Roche Pharma AG), ebenfalls ein VEGF-Inhibitor, der für die Behandlung bei Darmkrebs entwickelt wurde und nur hierfür zugelassen ist.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Aiello LP, Edwards AR, Beck RW, Bressler NM, Davis MD, Ferris F, Glassman AR, Ip MS, Miller KM (2010) Diabetic Retinopathy Clinical Research Network. Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology 117: 946–953
Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, Ferrara N, King GL, Smith LE (1995) Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGFreceptor chimeric proteins. Proc Natl Acad Sci USA 92: 10457–10461
Browning AC, Dua HS, Amoaku WM (2008) The effect of growth factors on the proliferation and in vitro angiogenesis of human macular inner choroidal endothelial cells. Br J Ophthalmol 92: 1003–1008
Carneiro A, Falcao M, Pirraco A, Milheiro-Oliveira P, Falcao-Reis F, Soares R (2009) Coparative effects of bevacizumab, ranibizumab, pegaptanib at intravitreal dose range on endothelial cells. Exp Eye Res 88: 522–527
Costa R, Carneiro A, Rocha A, Pirraco A, Falcao M, Vasques L, Soares R (2009) Bevacizumab and ranibizumab on microvascular endothelial cells: A comparative study. J Cell Biochem 108: 1410–1417
Cunningham ET Jr, Adamis AP, Altaweel M et al.; Macugen Diabetic Retinopathy Study Group (2005) A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112: 1747–1757
Diabetic Retinopathy Clinical Research Network (2008) Randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 115: 1447–1459
Early Treatment Diabetic Retinopathy Study Research Group (1985) Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 103: 1796–1806
Erickson KK, Sundstrom JM, Antonetti DA (2007) Vascular permeability in ocular disease and the role of tight junctions. Angiogenesis 10: 103–117
Friburg TR, Tolentino M, LEVEL Study Group, Weber P, Patel S, Campbell S, Goldbaum M (2010) Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL study. Br J Ophthalmol 94: 1611–1617
Furguson TA, Apte RS (2008) Angiogenesis in eye disease: immunity gained or immunity lost? Semin Immunopathol 30: 111–119
Gandreault J, Fei D, Rusit J, Suboc P, Shin V (2005) Preclinical pharmacokinetics of Ranibizumab (Ahu Fab V2) after a single intravitreal administration. Invest. Ophthalmol Vis Sci 46: 726–733
Heiduschka P, Fietz H, Hofmeister S et al.; The Tübingen Bevacizumab Study Group (2007) Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 48: 2814–2823
Hussain N, Ghanekar Y, Kaur J (2007) The future implications of anti-vascular endothelial growth factor therapy in ophthalmic practise. Indian J Ophthalmol 55: 445–450
Inan ÜÜ, Avci B, Kusbeci T, Kaderli B, Avci R, Temel SG (2007) Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. Invest Ophthalmol Vis Sci 48: 1773–1781
Joussen AM, Smyth N, Niessen C (2007) Pathophysiology of diabetic macular edema. Dev Ophthalmol 39: 1–12
Klettner A, Roider J (2008) Comparison if Bevacizumab, Ranibizumab and Pegaptanib in vitro: efficiency and possible additional pathways. Invest Ophthalmol Vis Sci 49: 4523–4527
Marneros AG, Fan J, Yokoyama Y, Gerber HP, Ferrara N, Crouch RK, Olsen BR (2005) Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am J Pathol 167: 1451–1459
Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, Mitchell P, Sharp D, Wolf-Schnurbusch UE, Gekkieva M, Weichselberger A, Wolf S (2010) Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-months randomized controlled double-masked multicenter phase II study. Diabetes Care 33: 2399–2405
Mitchell P, Korobelnik JF, Lanzetta P, Holz FG, Prünte C, Schmidt-Erfurth U, Tano Y, Wolf S (2010) Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials
Nicholson BP, Schachat AP (2010) A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 248: 915–930
Nishijima K, Ng YS, Zhong L et al. (2007) Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. AJP 171: 53–67
Peters S, Heiduschka P, Julien S, Ziemssen, F, Fietz H, Bartz-Schmidt KU, Schraermeyer U (2007) Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 143: 995–1002
Resnikoff S, Pascolini D, Etya’ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP (2004) Global data on visual impairment in the year 2002. Bull World Health Organ 82: 844–851
Schmidt-Erfurth U (2010) Clinical safety of renibizumab in age-related macular degeneration. Expert Opin Drug Saf Evaluation 9: 149–165
Simó R, Carrasco E, García-Ramírez M, Hernández C (2006) Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr Diabetes Rev 2: 71–98
Spitzer MS, Yoeruck E, Sierra A, Wallenfels-Thilo B, Schraermeyer U, Spitzer B, Bartz-Schmidt K, Szurman P (2007) Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells, Graefes Arch Clin Exp. Ophthalmol 245: 1937–1842
Stefánsson E (2001) The therapeutic effects of retinal laser treatment and vitrectomy. A theory based on oxygen and vascular physiology. Acta Ophthalmol Scand 79: 435–440
Sugimato H, Hamamo Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A, Kalluri R (2003) Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 278: 12605–12608
Wang X, Wang G, Wang Y (2009) Intravitreous vascular endothelial growth factor and hypoxia-inducible factor 1a in patients with proliferative diabetic retinopathy. Am J Ophthalmol 148: 883–889
Wang Y, Fei D, Vanderlaan M, Song A (2004) Biological activity of bevacizumab, a humanizied anti-VEGF antibody in vitro. Angiogenesis 7: 223–345
Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, Farah ME, Maia M, Roca JA, Rodriguez FJ, Pan American Collaborative Retina Group (PACORES) (2008) Twelf-month safety of intravitreal injections of bevazizumab (Avastin); results of the Pan American Collaborative Retina Group (PACORES). Graefes Arch Clin Exp Ophthalmol 246: 81–87
Ziemssen F, Zhu Q, Peters S, Grisanti S, ELW ar dani M, Szurman P. Bartz-Schmidt KU, Tuebingen Bevacizumab Studygroup, Ziemssen T (2008) Intensified monitoring of circadian blood pressure and heart rate before and after intravitreous injection of bevacizumab: preliminary findings of a pilot study. Int Ophthalmol 29: 213–224
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Medizin Verlag Heidelberg
About this chapter
Cite this chapter
Engelmann, K., Becker, K.A. (2011). Pegaptanib zur Behandlung des diabetischen Makulaödems. In: Glaukom und Makula 2010. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-22054-8_10
Download citation
DOI: https://doi.org/10.1007/978-3-642-22054-8_10
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-22053-1
Online ISBN: 978-3-642-22054-8
eBook Packages: Medicine (German Language)